MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Vesomni 6mg/0.4mg modified-release tablets (Astellas Pharma Ltd).

Stability Notes

Store in airtight containers. Protect from light.

Provenance

This compatibility recommendation is derived from generic co-codamol 30mg/500mg tablets.

Stability Notes

Soluble tablets - unsuitable for MCA.

Provenance

This compatibility recommendation is derived from Solpadol 30mg/500mg effervescent tablets (Sanofi) and generic co-codamol 30mg/500mg effervescent tablets.

Stability Notes

Store in nonmetallic, airtight containers. Original packaging contains a desiccant.

Provenance

This compatibility recommendation is derived from Solvazinc 125mg effervescent tablets (Galen Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Seroquel XL 50mg tablets (Luye Pharma Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Seroquel 200mg tablets (Luye Pharma Ltd) and Quetiapine 200mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Seroquel 200mg tablets (Luye Pharma Ltd) and Quetiapine 200mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Seroquel XL 300mg tablets (Luye Pharma Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Seroquel XL 300mg tablets (Luye Pharma Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Seroquel XL 400mg tablets (Luye Pharma Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.